Key Details
Price
$78.60Annual Revenue
$3.62 BAnnual EPS
$1.30Annual ROE
25.78%Beta
0.39Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Oct 24, 2024Recent annual earnings:
Feb 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 13, 2022Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
DexCom and Albemarle are included in the Zacks Investment Ideas article.
On Monday, Abbott Laboratories announced that it has come to an agreement with DexCom to resolve all patent conflicts concerning continuous glucose monitoring devices.
DexCom (DXCM) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. Recent changes in earnings estimates may lead to an additional increase in the stock price soon.
The shares of DexCom, a company that makes medical devices, have fallen by 37% this year. Investors were let down by the company's second-quarter results, which caused a significant drop in its stock price overnight.
NEW YORK--(BUSINESS WIRE)--EDO, a company focused on TV outcomes, has published its Q3 2024 report on Diabetes Convergent TV Outcomes. This report offers important insights into how linear and streaming TV ads perform in the diabetes sector, highlighting key factors that influence consumer engagement. It shows that GLP-1 drugs are changing diabetes management and that advertisers are putting more money into convergent TV to reach this expanding audience.
Dexcom has introduced the first Generative AI platform for glucose biosensing. This new technology aims to improve the way glucose levels are monitored.
On Tuesday, Dexcom revealed its first generative AI feature for the Stelo biosensor, which provides users with a customized weekly report on their glucose levels. The company has been developing a generative AI platform using technology from Google Cloud.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a leader in glucose monitoring, has introduced a unique Generative AI (GenAI) platform, becoming the first continuous glucose monitor (CGM) maker to use GenAI in its technology. This new platform will examine personal health data to show how lifestyle choices affect glucose levels and offer practical advice to enhance metabolic health.
In 2024, DexCom is dealing with challenges from competition and some mistakes, but the future for continuous glucose monitors looks promising. In the third quarter, their revenue increased by just 2% year-on-year to $994.2 million, affected by both short-term and long-term difficulties that impacted growth and profit margins. They launched a new over-the-counter product called Stelo CGM in August, which aims to attract non-insulin users, and they expect significant growth from it in 2025.
DexCom, a specialist in medical devices, is currently facing challenges. Its stock has dropped significantly this year because of disappointing financial performance, and some of the difficulties it has faced are certainly worrying.
FAQ
- What is the primary business of DexCom?
- What is the ticker symbol for DexCom?
- Does DexCom pay dividends?
- What sector is DexCom in?
- What industry is DexCom in?
- What country is DexCom based in?
- When did DexCom go public?
- Is DexCom in the S&P 500?
- Is DexCom in the NASDAQ 100?
- Is DexCom in the Dow Jones?
- When was DexCom's last earnings report?
- When does DexCom report earnings?
- Should I buy DexCom stock now?